Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.06 – $0.23
4% from low
Exchange
OTC Link
OS
Borrow rate
10.21%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.9M | $45.6M | $50.9M | $121.5M | $134.0M | $148.6M | $158.0M | $159.8M |
| Cost of revenue | $4.0M | $26.9M | $19.6M | $55.2M | $70.1M | $82.7M | $95.1M | $101.9M |
| Gross profit | $7.8M | $18.7M | $31.3M | $66.3M | $64.0M | $65.9M | $62.9M | $57.9M |
| Gross margin | 65.9% | 41.0% | 61.5% | 54.6% | 47.7% | 44.4% | 39.8% | 36.2% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$5.4M | $5.6M | $14.5M | $26.9M | $20.4M | $15.1M | $2.9M | −$2.1M |
| EBITDA | −$8.3M | −$67.9M | $16.5M | $29.0M | $25.9M | $11.2M | $13.8M | $9.4M |
| Net income | −$13.6M | −$66.5M | $2.1M | $7.2M | $13.5M | −$16.0M | −$12.2M | −$14.5M |
| Net margin | -114.8% | -145.9% | 4.2% | 5.9% | 10.0% | -10.8% | -7.7% | -9.1% |
| EPS (diluted) | -0.07 | -0.32 | 0.01 | 0.02 | 0.04 | -0.04 | -0.03 | -0.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $161M | $-0.04 | $-0.05–$-0.04 | 1 |
| 2027 | $170M | $-0.03 | $-0.03–$-0.02 | 1 |
| 2028 | $171M | $-0.02 | $-0.02–$-0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
MARIMED INC
No one on the platform currently holds MRMD.
No tracked institution reports a position in MRMD as of their last filing.
No one on the platform has traded MRMD yet.
| $4731 |
| — |
| LEEEFLeef Brands Inc. | $0.17 | +0.00% | $35M | — |
| MILFF1CM Inc. | $0.08 | +0.00% | $9M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 0.2× sales vs its 0.9× historical median P/S.
Fair value ≈ $0.39 · price $0.07 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MRMD 🗑️ Revenue : 160 million a year Market cap : 27 million Still not a buyer in sight. This 🗑️ is controlled by majority of trades under $100 all day everyday. “Shareholder value” @MRMDIR
View on StockTwits ↗$MRMD Why does Wall Street hate this management team so much? Why has Wall Street priced thiscompany for bankruptcy? Why does the entire investment community think John Levine is a brainless moron? Asking for a friend
View on StockTwits ↗$MRMD Market had a great day. Sector had a nice day. This trash RED and DEAD as always. 🗑️
View on StockTwits ↗$MRMD Hearings start today for full S3. Next we will get banking. We already got medical S3 the president is making moves and the constant historical reform and progress being made is at all time highs. And this 🗑️ is dead at .07
View on StockTwits ↗$MRMD The DEA applications (filed right in the expedited window) are a positive catalyst for federal alignment, potential tax relief (280E), and long-term legitimacy. Processing could take up to ~6 months (target for priority apps), with operations continuing uninterrupted under state licenses in the meantime. https://canndelta.com/services/dea-registrations-schedule-iii-medical-marijuana/
View on StockTwits ↗$MRMD The DEA has committed to making every effort to complete review within 6 months for timely submissions. This is not a strict legal deadline but a stated goal in the rescheduling rules. Standard (non-expedited) DEA registrations often take 4–8 weeks, but this cannabis-specific process is more complex due to the new framework, so the 6-month target for expedited cases is the relevant benchmark.
View on StockTwits ↗$MRMD MariMed Inc. (MRMD) announced on June 25, 2026, that it has submitted applications to the U.S. Drug Enforcement Agency (DEA) to register certain state-licensed medical cannabis operations. Aligns MariMed’s state-licensed medical cannabis businesses with federal requirements post-rescheduling. This is part of an expedited “fast-track” pathway for state licensees. State-licensed operators had until around June 27, 2026, for priority/expedited review (applications submitted in this window get processed faster, with interim operations allowed under state licenses during review).
View on StockTwits ↗$MRMD marijuana stocks are dead no news and no one cares
View on StockTwits ↗$MRMD Looking for reasonable thoughts about my contemplating selling MRMD(at a loss) and buying Village Farms(VFF) for the international exposure and possibly higher upside potential. Thoughts?
View on StockTwits ↗$MRMD complete 🗑️. How can you talk about top brands and shareholder value when your stock sits dead with no volume and trades less than $20K a day 🤡’s @MRMDIR
View on StockTwits ↗$MRMD Impossible to move with non existent volume. 10k blocks on the ask don’t even get touched. All you have to do is throw a 50k block up on the ask and watch this 🗑️ sit dead.
View on StockTwits ↗$MRMD https://www.marijuanamoment.net/dea-will-highlight-testimony-on-marijuanas-medical-benefits-in-rescheduling-hearing-new-filing-shows/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.